Product Name: Pomalidomide
Synonyms: Pomalidomide high quality;pomalidomide,Pomalyst;Actimid (Celgene);4-amino-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione;Pomalidomide high quality 19171-19-8;Pomalidomide, 99%, a inhibitor of TNF-α;4-Amino-2-(2,6-dioxo-piperidin-3-yl)-1H-isoindol-1,3(2H)-dione;4-Amino-2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione
CAS: 19171-19-8
MF: C13H11N3O4
MW: 273.24
EINECS: 805-902-5
Melting point  318.5 - 320.5°
Boiling point  582.9±45.0 °C(Predicted)
density  1.570±0.06 g/cm3(Predicted)
storage temp.  2-8°C
solubility  DMSO: ≥14mg/mL
pka 10.75±0.40(Predicted)
form  powder
color  yellow
Uses Pomalidomide inhibits LPS-induced TNF-α release with IC50 of 13 nM
Uses Pomalidomide is a thalidomide derivative, a potent inhibitor of TNF-α production. It is an antiinflammatory and antitumor agent used in the treatment of multiple myeloma.
Uses Pomalidomide is a second generation immunomodulator, TNF-α inhibitor, and thalidomide analog. An inhibitor of LPS-induced TNFαrelease.

Pomalidomide inhibits LPS-induced TNF-α release with IC50 of 13 nM in PBMCs.
Pomalidomide inhibits lipopolysaccharide (LPS) stimulated TNF-alpha release in human PBMC and in human whole blood with IC50 values of 13 nM and 25 nM, respectively. Pomalidomide inhibits the growth of T regulatory cells which is stimulated by IL-2 with an IC50 of ~1 μM. Treatment with Pomalidomide (6.4 nM-10 μM) increases the production of IL-2 in human peripheral blood T cells, and is slightly more potent in the CD4+ subset than in the CD8+ subset. Pomalidomide is significantly more potent than CC-5013 at elevating IL-2, IL-5, and IL-10 levels, but only slightly more potent than CC-5013 at elevating IFN-γ levels.
Pomalidomide enhances SEE and Raji cells induced AP-1 transcriptional activity in Jurkat cells in a dose-dependent manner, with a maximal enhancement of 4-fold at 1 μM. Exposure of Raji cells to various concentrations of Pomalidomide (2.5-40 μg/mL) for 48 hours leads to a significant decrease in cell proliferation and DNA synthesis. There is a reduction of ~40% compared to vehicle-treated controls.